Xolair

Xolair Article Summary

Recent Xolair Forums  Start a New Discussion  View All  

Xolair Warning Label Both the FDA and Health Canada have issued warnings about this pharmaceutical. FDA Proposes to Strengthen Label Warning for Xolair February 21, 2007 - "The Food and Drug Administration (FDA) announced that it has requested Genentech, Inc. add a boxed warning to the product label for omalizumab, marketed as Xolair. The boxed warning emphasizes that Xolair, used to treat patients with asthma related to allergies, may cause anaphylaxis. Anaphylaxis may include trouble breathing, chest tightness, dizziness, fainting, itching and hives, and swelling of the mouth and throat. In addition, FDA has asked Genentech to revise the Xolair label and provide a Medication Guide for patients to strengthen the existing warning for anaphylaxis." http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108850.htm Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) July 16, 2009 - "FDA is evaluating interim safety findings from an ongoing study of Xolair (omalizumab) that suggests an increased number of cardiovascular and cerebrovascular adverse events in a group of patients using Xolair compared to a group of patients not given the drug (control group). Xolair is approved for use by adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who test positive for reactivity to a perennial airborne allergen, and whose symptoms are inadequately controlled with inhaled corticosteroids. The ongoing study, titled Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS), is an observational study of approximately 5000 Xolair treated patients and a control group of approximately 2500 non-Xolair treated patients. The primary objective of the EXCELS study is to assess the long-term safety profile of Xolair in patients followed for 5 years. Study patients are 12 years of age and older with moderate to severe persistent asthma and who have a positive skin test or blood test for an aeroallergen. The interim data, submitted by the manufacturer of Xolair (Genentech), suggests a disproportionate increase in ischemic heart disease, arrhythmias, cardiomyopathy and cardiac failure, pulmonary hypertension, cerebrovascular disorders, and embolic, thrombotic and thrombophlebitic events in patients treated with Xolair compared to the control group of patients not given the drug. FDA is not recommending any changes to the prescribing information for Xolair and is not advising patients to stop taking Xolair at this time. Until the evaluation of the EXCELS study is completed, healthcare providers and patients should be aware of the risks and benefits described in the prescribing information, as well as the new information from the ongoing EXCELS study that may suggest a risk of cardiovascular and cerebrovascular adverse events." http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety...ucm172218.htm Friday, 8/14/2009 1:30:47 AM  Post a Reply

Xolair MY SIDE EFFECTS ENCLUDE- SWELLING IN FEET AND LEGS UP TO THE KNEES. FEET ARE TENDER TO WALK ON MAINLY IN THE HEELS. MEMORY HAS NOT BEEN GOOD AND CANNOT CONCENTRATE. Wednesday, 9/6/2006 7:48:26 AM  1 Reply

Possible Dosages for this and Related Drugs:

Related Drug Page(s):

Webmasters or Publishers: Link To This Drug Listing

LEARN ABOUT Xolair www.PrescriptionDrug-Info.com